Showing papers by "Jana Markova published in 2015"
University of St. Gallen1, VU University Medical Center2, Charles University in Prague3, University of Würzburg4, University of Tübingen5, Charité6, Heidelberg University7, Rolf C. Hagen Group8, Otto-von-Guericke University Magdeburg9, University of Cologne10, Hamm AG11, University of Erlangen-Nuremberg12, Cochrane Collaboration13
TL;DR: Non-inferiority of the experimental variants compared with ABVD in terms of freedom from treatment failure (FFTF) is shown by excluding a difference of 6% after 5 years corresponding to a hazard ratio (HR) of 1.72, via a 95% CI.
140 citations
TL;DR: The prognosis of NLPHL is excellent, and rituximab combined with chemotherapy and/or radiotherapy appears to prevent disease progression/relapse.
Abstract: Background: Nodular lymphocyte-predominant Hodgkin's lymphoma
(NLPHL) is a rare subtype of Hodgkin's lymphoma showing strong
CD20 expression. The role of rituximab in treating NLPHL still
needs clarification. Methods: We retrospectively reviewed the
outcome of 23 patients with NLPHL treated with rituximab alone
or in combination with chemotherapy and/or radiotherapy as part
of their first-or second-line treatment. Results: The median
follow-up of the whole group was 67 months, and all patients
remained alive. Twenty-two patients achieved complete remission
after rituximab-based therapy, and one of them relapsed 32
months after treatment. One patient treated with rituximab
alone achieved partial remission and progressed 22 months after
treatment. Conclusion: The prognosis of NLPHL is excellent.
Rituximab combined with chemotherapy and/or radiotherapy
appears to prevent disease progression/relapse.
5 citations
TL;DR: It is suggested that spontaneous anti-NPM immune response may prevent AML development and helps achieve durable cure, and NPMc+ AML patients with favorable HLA type could benefit from an immunomodulatory therapy.
1 citations